http://lookfordiagnosis.com
English
Spanish
Italian
Portuguese
French
Swedish
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 ...
GBI Research, the leading business intelligence provider, has released its latest research,'Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact ...
PR Newswire (press release) - Wed, 23 Apr 2014 10:15



FDA Approves Ramucirumab for Gastric and GEJ Adenocarcinoma
The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) as a treatment for patients with unresectable gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma following fluoropyrimidine- or platinum-containing therapy, based on a ...
OncLive - Mon, 21 Apr 2014 17:22

US FDA approves Lilly's Cyramza to treat advanced gastric cancer after prior ...
pharmabiz.com - Tue, 22 Apr 2014 20:32

New Gastric Cancer Drug Gets FDA Approval
Monthly Prescribing Reference - Mon, 21 Apr 2014 14:02

Breaking News: Gastric Cancer Drug Approved
Drug Discovery & Development - Tue, 22 Apr 2014 06:07

Lilly announces FDA approval of new cancer treatment
Fox 59 - Mon, 21 Apr 2014 23:56

Cyramza approved by FDA for stomach cancer
Oncology Nurse Advisor - Tue, 22 Apr 2014 09:30

Lilly's CYRAMZA™ (ramucirumab) Becomes First FDA-Approved Treatment for ...
MarketWatch - Mon, 21 Apr 2014 18:19

Ganetespib trial hints at survival benefit in lung adenocarcinoma
Tested in combination with docetaxel, the experimental drug appeared to improve overall and progression-free survival, compared with docetaxel alone, as second-line therapy for patients with advanced non–small cell adenocarcinoma of the lung, Dr ...
The Oncology Report - Mon, 21 Apr 2014 13:15

Research and Markets: Global Pancreatic Adenocarcinoma Therapeutics in ...
The current Pancreatic Cancer (PC) therapeutics market is very limited, with only four drugs approved for the treatment of the disease. These are the generics gemcitabine and fluorouracil (5-FU) and the patented drugs Tarceva, by Genentech and Roche ...
Business Wire (press release) - Tue, 22 Apr 2014 06:15

Pancreatic Adenocarcinoma Therapeutics Market Analysis & 2019 Forecasts
Dallas, TX -- (SBWIRE) -- 04/21/2014 -- RnRMarketResearch.com adds new market research report “Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 – Early Stage Pipeline Shows Diversity of Novel Targets though Commercial ...
DigitalJournal.com - Mon, 21 Apr 2014 10:48

Survival greater in esophageal adenocarcinoma patients previously diagnosed ...
The small proportion of patients with esophageal adenocarcinoma previously diagnosed with Barrett's esophagus exhibited improved survival compared with those without a previous diagnosis in a recent study. Researchers in Northern Ireland conducted a ...
Healio - Thu, 10 Apr 2014 07:26

Acute pancreatitis may be predictor of pancreatic adenocarcinoma
Many patients with pancreatic adenocarcinoma initially presented with an episode of acute pancreatitis, and as long as 2 years elapsed between diagnoses, according to results of a retrospective study. The correlation appeared particularly strong in ...
Healio - Tue, 25 Mar 2014 07:03

Global Pancreatic Adenocarcinoma Therapeutics Market to Reach $1.2 billion in ...
Pancreatic Adenocarcinoma Therapeutics Market in Major Developed Markets to 2019 is a new pharma report announced by Reportstack. This report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers ...
WhaTech - Mon, 07 Apr 2014 14:02


1  2  3  4  5  6  7  8    ->

Last update: April 2009
Statistics